Relationship among chelator adherence, change in chelators, and quality of life in Thalassemia

Quality of Life Research

Volumn 23, Issue 8, 2014, Pages 2277-2288

  Trachtenberg, Felicia L ^a   Gerstenberger, Eric ^a   Xu, Yan ^a   Mednick, Lauren ^b   Sobota, Amy ^b   Ware, Hannah ^c   Thompson, Alexis A ^d   Neufeld, Ellis J ^b   Yamashita, Robert ^e  

^a NEW ENGLAND RESEARCH INSTITUTES   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d CHILDREN'S MEMORIAL HOSPITAL   (United States)

^e CALIFORNIA STATE UNIVERSITY   (United States)

Author keywords

Adherence; Iron chelation; Quality of life; Thalassemia

Indexed keywords

DEFERASIROX; DEFEROXAMINE; DRUG ADMINISTRATION; IRON; IRON CHELATING AGENT;

ADOLESCENT; ADULT; AGE; ARTICLE; BETA THALASSEMIA; CANADA; CHELATION THERAPY; CHILD; CHRONIC DISEASE; COHORT ANALYSIS; DRUG SUBSTITUTION; DRUG THERAPY; DRUG WITHDRAWAL; ETIOLOGY; FAMILY; FEMALE; HEALTH SURVEY; HUMAN; INFANT; IRON OVERLOAD; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; METABOLISM; MIDDLE AGED; MONOTHERAPY; PATIENT PREFERENCE; PERSONAL NEEDS; PRESCHOOL CHILD; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; SELF REPORT; SMOKING; SOCIAL INTERACTION; STATISTICS; THALASSEMIA; UNITED KINGDOM; UNITED STATES; UNSPECIFIED SIDE EFFECT; YOUNG ADULT;

ADMINISTRATION AND DOSAGE; ADOLESCENT; ADULT; CHELATION THERAPY; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; COHORT STUDIES; DRUG THERAPY; ETIOLOGY; FEMALE; HUMANS; INFANT; IRON CHELATING AGENTS; IRON OVERLOAD; LONGITUDINAL STUDIES; MALE; MEDICATION ADHERENCE; METABOLISM; MIDDLE AGED; PSYCHOLOGY; QUALITY OF LIFE; STATISTICS AND NUMERICAL DATA; THALASSEMIA; YOUNG ADULT;

EID: 84909641711     PISSN: 09629343     EISSN: 15732649     Source Type: Journal    
DOI: 10.1007/s11136-014-0671-2     Document Type: Article

References (15)

1. US Department of Health and Human Services. Office of Disease Prevention and Health Promotion. Healthy People 2020. Washington, DC. Available at http://www.healthypeople.gov/2020/about/qolwbabout.aspx. Accessed 1/30/14.
2. Trachtenberg, F., et al. (2011). Iron chelation adherence to deferoxamine and deferasirox in thalassemia. American Journal of Hematology,86(5), 433–436.
3. Sobota, A., et al. (2011). Quality of life in thalassemia: a comparison of SF-36 results from the thalassemia longitudinal cohort to reported literature and the US norms. American Journal of Hematology,86(1), 92–95.
4. Mednick, L., et al. (2010). Symptoms of depression and anxiety in patients with thalassemia: Prevalence and correlates in the thalassemia longitudinal cohort. American Journal of Hematology,85(10), 802–805.
5. Yamashita, R., Sobota, A., Trachtenberg, F., Xu, Y., Quinn, C. T., Vichinsky, E. P., Haines, D., Kleinert, D. A., Schilling, L., Pakbaz, Z., Boudreaux, J., Odame, I., Thompson, A. A., Giardina, P. J., Kwiatkowski, J. L., Neufeld, E. J. (2013). The impact of the child with Thalassemia on the family: Parental assessments. in press.
6. Messina, G., et al. (2008). Psychosocial aspects and psychiatric disorders in young adult with thalassemia major. Internal and Emergency Medicine,3(4), 339–343.
7. Scalone, L., et al. (2008). Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: The ITHACA study. Current Medical Research and Opinion,24(7), 1905–1917.
8. La Nasa, G., et al. (2013). Long-term health-related quality of life evaluated more than 20 years after hematopoietic stem cell transplantation for thalassemia. Blood,122(13), 2262–2270.
9. Payne, K. A., et al. (2008). Iron chelation therapy: Clinical effectiveness, economic burden and quality of life in patients with iron overload. Advances in Therapy,25(8), 725–742.
10. Payne, K. A., et al. (2007). Clinical and economic burden of infused iron chelation therapy in the United States. Transfusion,47(10), 1820–1829.
11. Gollo, G., et al. (2013). Changes in the quality of life of people with thalassemia major between 2001 and 2009. Patient Preference and Adherence,7, 231–236.
12. Snaith, R., & Zigmond, A. (1994). The Hospital Anxiety and Depression Scale Manual. London, UK: nferNelson.
13. Ware, J. E., et al. (2007). User’s Manual for the SF-36v2 Health Survey (2nd ed.). Lincoln, RI: Quality Metric Incorporated.
14. Landgraf, J. M., Abetz, L., & Ware, J. E. (2006). Child Health Questionnaire (CHQ): A User’s Manual. Third Printing. Lincoln, RI: Quality Metric Incorporated.
15. Cook, C. E. (2008). Clinimetrics corner: The minimal clinically important change score (MCID): A necessary pretense. Journal of Manual & Manipulative Therapy,16(4), E82–E83.